血清代谢的变化预测了耐药性
Wenzhong Kang1, Qingrong Han2, Min Chen1
1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, #1 Jianshe East Road, Zhengzhou, 450052, China.
Scientific reports
|December 3, 2025
概括
这项研究使用血清代谢物水平开发了耐药性 (DRE) 的早期预测模型. 该模型显示出作为一种非侵入性工具的承诺,用于识别可能受益于向代谢疗法的患者.
科学领域:
- 神经学 神经学
- 代谢学 代谢学 代谢学
- 生物化学 生物化学
背景情况:
- 耐药性 (DRE) 是一个重大的临床挑战,原因是缺乏可靠的早期预警系统.
- 确定可能患有DRE的患者对于及时干预和个性化治疗策略至关重要.
研究的目的:
- 开发和验证DRE的预测模型,使用基线血清代谢物概况.
- 确定与DRE.发展相关的特定代谢途径和生物标志物.
主要方法:
- 一项前性队列研究,涉及151名患者.
- 使用非目标方法进行血清代谢分析.
- 开发一个包含代谢物和临床数据的支持矢量机 (SVM) 模型.
主要成果:
- 与非药物耐药性 (NDRE) 相比,在DRE组中发现了215种明显变化的代谢物,其中176种降低调节,39种上调调节.
- 关键的代谢途径包括脂,胆,酸和α-酸代谢.
- 在训练组中,SVM模型实现了0.9396的AUC,在独立测试组中达到0.7437.
结论:
- 基线血清代谢物水平可以预测DRE的发展.
- 开发的模型为早期DRE识别提供了一个非侵入性,客观的工具.
- 这些发现支持了针对性代谢疗法的潜力,用于管理DRE.
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
196
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
196
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
791
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
791
Antiepileptic Drugs: Glutamate Antagonists
863
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
863
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K


